Cancer survival in the U.S. has climbed to 70%, reflecting major advances in treatment, early detection and personalized care ...

The latest edition of an annual report finds new cases continue to rise and outcomes have worsened for some cancers.

New data from the American Cancer Society shows major progress in cancer survival, with nearly 70% of people now living at ...

Prostate cancer patients with metastatic disease and low-volume primary tumors appear to have a poor prognosis, according to ...

SGLT2 inhibitor use was associated with a significantly lower risk for androgen deprivation therapy (ADT) failure and next-generation hormonal agent failure in men with prostate cancer. SGLT2 ...

Using de-identified data from the National Cancer Institute, researchers followed 205 patients—average age, 61 years—with prostate cancer and preexisting depression. Patients with both conditions had ...

The Alliance for Clinical Trials in Oncology has launched a randomized phase III clinical trial called RECIPROCAL (Alliance ...

The five-year survival rate for all cancers combined has reached a historic 70%, according to the latest American Cancer Society Cancer Statistics 2026 report, based on people diagnosed in the U.S.

PROSTATE cancer has become the most common form of the disease in Britain for the first time. Analysis of NHS figures by ...

Cancer charity highlights apparent ‘postcode lottery’ of testing and diagnoses across different regions seen in study ...

Prostate cancer has been found to be the most common cancer among men in South Korea. While lung cancer had previously been ...